key: cord-0791767-45elkd10
authors: Gan, Esther S.; Syenina, Ayesa; Linster, Martin; Ng, Benson; Zhang, Summer L.; Watanabe, Satoru; Rajarethinam, Ravisankar; Tan, Hwee Cheng; Smith, Gavin JD.; Ooi, Eng Eong
title: A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection
date: 2021-07-08
journal: Antiviral Res
DOI: 10.1016/j.antiviral.2021.105138
sha: d4e27230abc51bbf41cb0a95a20bf12f3d109dab
doc_id: 791767
cord_uid: 45elkd10

The global spread of SARS-CoV-2 has made millions ill with COVID-19 and even more from the economic fallout of this pandemic. Our quest to test new therapeutics and vaccines require small animal models that replicate disease phenotypes seen in COVID-19 cases. Rodent models of SARS-CoV-2 infection thus far have shown mild to moderate pulmonary disease; mortality, if any, has been associated with prominent signs of central nervous system (CNS) infection and dysfunction. Here we describe the isolation of SARS-CoV-2 variants with propensity for either pulmonary or CNS infection. Using a wild-type SARS-CoV-2 isolated from a COVID-19 patient, we first found that infection was lethal in transgenic mice expressing the human angiotensin I-converting enzyme 2 (hACE2). Fortuitously, full genome sequencing of SARS-CoV-2 from the brain and lung of these animals showed genetic differences. Likewise, SARS-CoV-2 isolates from brains and lungs of these also showed differences in plaque morphology. Inoculation of these brain and lung SARS-CoV-2 isolates into new batch of hACE2 mice intra-nasally resulted in lethal CNS and pulmonary infection, respectively. Collectively, our study suggests that genetic variants of SARS-CoV-2 could be used to replicate specific features of COVID-19 for the testing of potential vaccines or therapeutics.

from the economic fallout of this pandemic. Our quest to test new therapeutics and 23 vaccines require small animal models that replicate disease phenotypes seen in 24 COVID-19 cases. Rodent models of SARS-CoV-2 infection thus far have shown mild 25 to moderate pulmonary disease; mortality, if any, has been associated with prominent 26 signs of central nervous system (CNS) infection and dysfunction. Here we describe 27 the isolation of SARS-CoV-2 variants with propensity for either pulmonary or CNS 28 infection. Using a wild-type SARS-CoV-2 isolated from a COVID-19 patient, we first 29 found that infection was lethal in transgenic mice expressing the human angiotensin 30 I-converting enzyme 2 (hACE2). Fortuitously, full genome sequencing of SARS-CoV-31 2 from the brain and lung of these animals showed genetic differences. Likewise, 32 SARS-CoV-2 isolates from brains and lungs of these also showed differences in 33 plaque morphology. Inoculation of these brain and lung SARS-CoV-2 isolates into new 34 batch of hACE2 mice intra-nasally resulted in lethal CNS and pulmonary infection, 35

respectively. Collectively, our study suggests that genetic variants of SARS-CoV-2 36 could be used to replicate specific features of COVID-19 for the testing of potential 37 vaccines or therapeutics. 38

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which 42 emerged at the end of 2019 in China, has spread throughout the world to cause the 43 coronavirus disease-19 pandemic. Millions have developed and ~2.5% of whom have died from respiratory dysfunction (L. Wang et al., 2020) . 45

Some have also developed severe systemic complications, such as coagulopathy 46 (Zhou et al., 2020) . Vaccine development has made unprecedented progress 47 amplicon-based framework (https://www.protocols.io/view/ncov-2019-sequencing-142 protocol-v3-locost-bh42j8ye). Briefly, cDNA was synthesized from RNA extracted from 143 lung and brain tissues using the SuperScript IV First-Strand Synthesis System (Life 144

Technologies) with random hexamers. Amplicons were then generated using Q5 Hot 145 To determine the clinical outcome of SARS-CoV-2 infection in K18-hACE2 184 mice, two groups of mice aged 6-8 weeks (n=4 per group) were intranasally inoculated 185 with 2x10 5 (high dose) or 2x10 4 PFU (low dose) of SARS-CoV-2 (SG12) (hCoV-186 19/Singapore/2/2020); the full genome sequence of SG12 has been previously 187 reported in GSAID (EPI_ISL_407987) (Su et al., 2020) . All animals were observed 188 daily for weight loss and other clinical signs for 8 days ( Figure 1A ). Two out of four 189 (50%) animals inoculated with low-dose but not high-dose SARS-CoV-2 showed 190 weight loss from 3 days post infection (dpi) onwards. At 4 dpi, both groups of infected 191 K18-hACE2 mice exhibited lethargy and weight loss, with the exception of one animal 192 inoculated with low-dose SARS CoV-2 ( Figure 1B ). Signs of CNS dysfunction, such 193 as tremor and non-responsiveness to stimuli ( Figure 1C ), as well as respiratory 194 distress (labored breathing) ( Figure 1D ) and were evident at 3 and 5 dpi, respectively, 195 in both groups of infected animals. CNS signs such as abnormal gait, shaking and 196 paralysis were, however, predominant (Supplementary Table 1 ). The total clinical 197 scores thus mostly reflected CNS dysfunction. Three out of four (75%) animals 198 inoculated with low-dose SARS-CoV-2 met euthanasia criteria (clinical scores above 199 10) and were thus sacrificed between 5 and 7 dpi ( Figure 1E Although infected mice died mostly of CNS dysfunction, we nonetheless asked 206 if SARS-CoV-2 infection in these animals produced pulmonary pathology consistent 207 with those found in fatal COVID-19 cases. We carried out histopathological 208 J o u r n a l P r e -p r o o f investigations on formalin-fixed lungs of K18-hACE2 mice at 5 dpi, which was 209 immediately before the onset of clinical signs that heralded mortality. Infection with 210 both low-and high-dose SARS-CoV-2 produced multifocal to coalescing interstitial 211 pneumonia in the lung parenchyma ( Figure 2A ). The alveoli were collapsed with 212 thickened and congested septa ( Figure 2B ). Infiltration of mononuclear cells such as 213 lymphocytes, macrophages and plasma cells were mainly observed at peri-vascular, 214 peri-bronchioles, alveolar septa and alveolar sacs ( Figure 2C ). Mild degree of 215 pulmonary oedema ( Figure 2D ) and occasional focal presence of haemorrhages were 216 present. Minimal focal necrosis of alveoli was also observed. Vacuolar degeneration 217 of lining epithelium was common from bronchus to terminal bronchioles ( Figure 2E ). 218

A semi-quantitative analysis of all four SARS-CoV-2 infected animal lungs suggest 219 that bronchiolar degeneration, septal thickening and mononuclear cell infiltration are 220 common virus induced pathological changes in K18-hACE2 mice ( Figure 2F ). These 221 findings are thus similar to previous observations on K18-hACE2 mouse model 222 (Oladunni et al., 2020; Yinda et al., 2021) , nonhuman primate infection model and 223

deceased COVID-19 patients (Rockx et al., 2020; C. Wang et al., 2020) . 224 225 3.3. Infectious SARS-CoV-2 re-isolated from the lung and brain of K18-hACE2 mice 226

We next examined the sites of infection in various organs of SARS-CoV-2 227 infected female K18-hACE2 mice at 5 dpi. The brain, lung, eyes, spleen, liver and 228 kidneys were dissected from infected animals and homogenized; clarified 229 homogenates were then inoculated onto Vero-E6 cells. Cytopathic effects were 230 observed in cells inoculated with lung and brain homogenates, but not those from the 231 other organs (Supplementary Figure 1) . To define the viral burden in the lungs and 232 brains at post mortem examination, we used plaque assay to quantify SARS-CoV-2 233 infectious particles in the lung and brain homogenates. SARS-CoV-2 plaque titers in 234 the brain homogenates were approximately 4 logs higher than those in the lung ( Figure  235 2G). Moreover, the plaque morphology of the brain SARS-CoV-2 isolates (SG12-B) 236

were punctate in size, which was in contrast to the extensive areas of plaques formed 237 from the lung-derived isolates (SG12-L) (Supplementary Figure 2A) . 238 239 3.4. Genomic differences in SARS-CoV-2 isolates from lung and brain homogenates 240

Differences in the plaque morphology of the brain and lung isolates suggest 241 viral adaptations during the course of infection that may be important for system-242 J o u r n a l P r e -p r o o f specific dysfunction. To test this possibility, we conducted full genome sequencing of 243 SARS-CoV-2 RNA extracted from brain and lung homogenates, without isolation in 244 cell lines, and compared these with the sequence of the SG12 viruspropagated in 245

Vero E6 cellsthat was inoculated into these animals. Compared to the original SG12 246 sequence, the virus we used for our infection study had 2 mutations in the ORF1ab, 247 one consensus changedeletion at nucleotide position 517 to 519 (an ATG 248 methionine deletion -M173del) ( Figure 3A and B) and a C7391T substitution (amino 249 acid substitution P2379L). These mutations were also present in both brain and lung 250 samples ( Figure 3A) . 251

Viruses isolated from the brain showed two consensus changes in the S gene 252 -C23524T nucleotide substitution that corresponded to substitution of histidine with 253 tyrosine (H655Y) ( Figure 3A and C) and A23617G nucleotide substitution that 254 substituted serine with glycine (S686G) ( Figure 3A and D). While A23617G was found 255 exclusively in the brain, C23524T was also found in the lung but as a non-consensus 256 mutation ( Figure 3A, Supplementary Figure 2B ). Interestingly, A23617G and C23524T 257 appeared to be mutually exclusive in brain samples: C23524T was observed in 6 out 258 of 10 brain isolates, while A23617G were found in the remaining 4 animals. However, To test if the genetic differences between the brain and lung isolates of SARS-268

CoV-2 influenced system-specific dysfunction, we isolated SARS-CoV-2 from these 269 SG12-B showed tremor and paralysis at 5 dpi; only 20% of animals infected with 278 SG12-L displayed such signs ( Figure 4D ). Conversely, SG12-L infected mice 279 displayed labored breathing starting at 6 dpi ( Figure 4E) ; none of the SG12-B infected 280 mice showed such sign of respiratory distress. Notably, while no difference in viral 281 load was found in the lung of SG12-L and SG12-B infected animals ( Figure 4F ), viral 282 load in the brain was significantly higher in SG12-B than SG12-L infected animals 283 ( Figure 4G) . Moreover, the plaque morphology of SARS-CoV-2 isolated from SG12-B 284 infected lungs were uniformly punctate and significantly smaller compared to those 285 recovered from the lungs of SG12-L infected mice ( Figure 4H ). In addition, further 286 sequencing of viruses isolated from the lungs of SG12-L infected mice revealed 287 identical sequence changes (517-519del and C23524T), suggesting that SG12-L is 288 genetically stable. 289

The presence of both SG12-L and SG12-B in both lung and brain tissues 290

indicates that the observed mutations were unlikely to determine tissue tropism. 291

Instead, these mutations could contribute to differential host responses. As 292 hyperinflammation has been associated with severe COVID-19, we measured the 293 RNA transcripts of inflammatory genes in the lungs and brains of SG12-L and SG12-294 B infected animals using a previously defined inflammation panel from Nanostring 295 technologies. Interestingly, despite comparable lung viral loads ( Figure 4F) , 296 inflammatory signatures identified from the lungs of SG12-L and SG12-B infected 297 animals clustered separately on a PCA plot ( Figure 5A ). Pathway analysis of the top 298 20 most correlated genes in PC1 that separated these gene clusters unsurprisingly 299 identified pathways in pathogen and inflammatory responses, specifically chemokine 300 signaling and cytokine-cytokine receptor interaction ( Figure 5B ). Strikingly, lungs of 301

the chemokine signaling pathway ( Figure 5C ) and cytokine-cytokine receptor signaling 303 pathway ( Figure 5D ). SG12-L also showed increased expression of genes such as 304 IL10, IFN, TNF and CXCL9 ( Figure 5E -H) (Oladunni et al., 2020) . Taken together, 305 these results further indicate that the genetic differences between SG12-L and SG12-306

Since the emergence of COVID-19, multiple murine infection models involving 310 transduced or transgenic mouse models expressing hACE2 to facilitate SARS-CoV-2 311 infection have been reported. These include mouse lines altered using permanent 312 genetic modifications such as CAG-hACE2, HFH4-hACE2 (Jiang et al., 2020) , 313 CRISPR/Cas9 knock-in of hACE2 (Sun et al., 2020) or using a mouse adapted SARS-314

CoV-2 (Dinnon et al., 2020) . However, the majority of these models displayed transient 315 weight loss and non-fatal extent of lung injury. While a lethal infection model has been 316 reported, lethality was observed exclusively in animals with detectable brain infection; 317 no lung injury nor weight loss was evident in this HFH4-hACE2 mouse model (Jiang 318 et al., 2020) . In addition to the above transgenic models, mice transduced with 319 adenovirus (Ad5-hACE2) or adeno-associated virus expressing hACE2 (AAV-hACE2) 320

have also been shown to be susceptible to SARS-CoV-2 infection, although these 321 animals manifest only mild, non-lethal disease (Israelow et al., 2020) . Besides our 322 current report, another group has also reported a lethal K18-hACE2 mouse 323 model (Golden et al., 2020) . This group observed considerable weight loss and >90% 324 lethality in SARS-CoV-2 infected mice. However, similar to the HFH4-hACE2 model, 325 lethality was evident in animals that developed a CNS infection. suggestive of CNS pathology (Song et al., 2020) , with entry to the CNS possibly via 330 the neural-mucosal interface in olfactory mucosa (Meinhardt et al., 2020) , the 331 dominant pathology and cause of death in most patients who succumbed to COVID-332 19 were respiratory dysfunction (Vincent and Taccone, 2020) . A mouse model that 333

reliably produces severe and lethal respiratory disease could thus be useful for testing 334 therapeutic and prophylactic strategies against the most common manifestation of 335 severe COVID-19acute respiratory distress. 336

The degree of disease severity observed in this K18-hACE2 model has been 337 attributed to the enhanced levels of hACE2 expression as compared to the other 338 transgenic animal models. The K18 promoter confers efficient transgenic expression 339 of hACE2 in respiratory epithelial cells. However, hACE2 expression has also been 340 observed in the colon, liver, kidney, gastrointestinal tract and brain albeit at low levels 341 of these animals (McCray et al., 2007b) . In our study, infection of this transgenic 342 mouse with wildtype SG12 produced both lung and brain infection. Although there was 343 J o u r n a l P r e -p r o o f lung pathology similar to what has been observed in fatal COVID-19 cases, the 344 prominent signs that led to euthanasia were mostly attributable to CNS rather than 345 respiratory dysfunction. The distinction in the genomic sequence between SARS-CoV-346 2 recovered from the lung compared to the brain of the infected animals, as 347 respectively exemplified by SG12-B and SG12-L, thus enabled us to derive viral 348 variants that induce mortality from respiratory rather than CNS dysfunction. These rate as compared to female mice (Golden et al., 2020) . Investigations on gender-355 specific response to SG12-L and SG12-B could thus also be informative. 356

The genome sequence differences between the lung-and brain-derived SARS-357

CoV-2 variants also suggest that mutations in the S1-S2 boundary may be important 358

in shaping system-specific pathology. We have focused on attention on high frequency 359 consensus changes only as a limitation of our study is the possibility of false positive 360 nucleotide substitutions among low frequency variants introduced at the PCR tiling 361 step. We identified two high frequency consensus changes C23524T (H655Y) and 362 A23617 (S686G), both residing in the S1-S2 boundary of the S protein, that were 363 present exclusively in the brain isolates. This region contains a polybasic sequence 364 motif -the cleavage site for the host proprotein convertase furin (Örd et al., 2020) . 365

Furin mediated cleavage results in S1-S2 to be non-covalently associated for further 366 priming by host serine protease, TMPRSS2, and has been shown to increase the 367 infectivity and tropism of SARS-CoV-2 (Walls et al., 2020) . In addition, furin cleavage 368 exposes the C terminus of the S1 protein which has recently been shown to increase 369 internalization of the virus via its CendR sequence binding to NRP1 (Daly et al., 2020) . 370

Due to its expression in the olfactory neurons, NRP1 has been found to mediate entry 371 of nanoparticles coated with SARS-CoV-2 derived CendR peptides into the olfactory 372 epithelium, neurons and blood vessels of the cortex (Cantuti-Castelvetri et al., 2020) . 373

Taken together, these observations collectively suggest that mutations near or at the 374 S1-S2 cleavage or CendR site may affect infectivity or pathology in the CNS, possibly 375 through spike glycoprotein fusogenicity (Walls et al., 2020) . Further studies will be 376 J o u r n a l P r e -p r o o f needed to determine how these mutations arise and the mechanism in which 377 mutations in the S1-S2 boundary shape CNS dysfunction. 378

In conclusion, the identification of SARS-CoV-2 variants that produce lethal 379 pulmonary or CNS infection in K18-hACE2 mice suggest the potential for further 380 development of small animal models for systems level specificity. These models could 381 also serve as resource for testing therapeutic and prophylactic candidates to prevent 382 specific organ dysfunction. 383 K18-hACE2 mice inoculated with 2x10 4 PFU revealed interstitial pneumonia as 574

represented by collapsed alveoli (asterisk) and multifocal inflammation in perivascular 575

(black arrows), peribronchiolar (white arrows), septa (blue arrows) and alveolar sacs 576 (yellow arrow) (A), alveolar septal thickening (arrow) and congestion (asterisk) (B), 577 mononuclear cells infiltration (arrow) in alveolar parenchyma (C) pulmonary oedema 578

(asterisk) displays pink stained homogenous materials that widens the interstitial area 579

and perivascular infiltration (arrow) (D) and bronchiole vacuolar degeneration marked 580 by cytoplasmic vacuolization (arrow) (E).

(F) Semi quantitative analysis of histopathological findings is based on subjective 582

scoring. 0-Nil, 1-Minimum, 2-Mild, 3-Moderate, 4-Marked, 5-Severe.

(G) Viral loads in the lungs and brains of infected mice 5 days post infection as 584 measured by plaque assay. 585 586 Figure 3 : Genetic differences in SARS-CoV-2 isolated from the brain and lungs 587 of infected K18-hACE2 mice 588

(A) SNVs mapped to its position in the SARS-CoV-2 genome. Red arrows depict 589 consensus mutations and black arrows depicts non-consensus mutations.

(B) SNV frequency of ATG deletion at nucleotide positions 517-519 in lung and brain 591 samples 592

(C) SNV frequency of C to T nucleotide substitution at position 23524 (H655Y) in lung 593 and brain samples 594 (D) SNV frequency of A to G nucleotide substitution at position 23617 (S686G) in lung 595 and brain samples 596 597 and SG12-L upon euthanasia measured by plaque assay.

(H) Representative images of lung plaque morphology from animals infected with 607 SD12-L and SG12-B. 608

The pathogenicity of SARS-413

CoV-2 in hACE2 transgenic mice

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Development of an epithelium-specific expression cassette with human DNA 424 regulatory elements for transgene expression in lung airways

Neuropilin-430 1 is a host factor for SARS-CoV-2 infection

A mouse-adapted model of SARS-CoV-2 to test COVID-436 19 countermeasures

440 Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-441

CoV-2 develop severe and fatal respiratory disease

Mouse model of 445 SARS-CoV-2 reveals inflammatory role of type I interferon signaling

Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2. 451 Cell

SARS-CoV-2 vaccines in development

Lethal infection of K18-hACE2 mice infected 460 with severe acute respiratory syndrome coronavirus

Lethal Infection of K18-hACE2 Mice Infected 465 with Severe Acute Respiratory Syndrome Coronavirus

Olfactory transmucosal 475 SARS-CoV-2 invasion as a port of central nervous system entry in individuals 476 with COVID-19

Lethality of SARS-CoV-2 infection 485 in K18 human angiotensin-converting enzyme 2 transgenic mice

The sequence at Spike S1/S2 site enables 488 cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 489 or MERS-CoV

Comparative pathogenesis of 495 COVID-19, MERS, and SARS in a nonhuman primate model

Qualitative and 498 quantitative analysis of nonneoplastic lesions in toxicology studies

Neuroinvasion of SARS-CoV-2 in human and mouse brain

Discovery and Genomic Characterization of a 382-Nucleotide 513

Deletion in ORF7b and ORF8 during the Early Evolution of SARS-CoV-2

A Mouse Model of SARS-CoV-2 Infection and 519 Pathogenesis

Understanding pathways to death in patients 521 with COVID-19

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

2020, n.d. Structure, 527 function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Receptor 530 Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on 531

Decade-Long Structural Studies of SARS Coronavirus

Alveolar macrophage dysfunction and cytokine storm in the 537 pathogenesis of two severe COVID-19 patients

Review of the 2019 novel coronavirus 540 (SARS-CoV-2) based on current evidence

SARS-CoV-2 545 infection of human ACE2-transgenic mice causes severe lung inflammation and 546 impaired function

K18-hACE2 mice develop respiratory 552 disease resembling severe COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-557 19 in Wuhan, China: a retrospective cohort study

SG12-L infection in lungs results in increased inflammatory responses 610 (A) PCA plot of inflammatory genes of SG12-L (red) and SG12-B (blue) infected lungs. 611 (B) Pathway analysis of the top

Heat map showing expression of genes in the chemokine and cytokine-cytokine 613 receptor signaling 614 (E-H) Normalized counts of genes expressed in SG12-B and SD12-L infected K18-615 hACE2 lungs